Rich Bendis And Jen Butler

Jennifer Butler, Executive Vice President and General Manager, Innate Pharma US Inc. joins Rich Bendis on BioTalk to discuss her career, bringing Innate from France to the US, and goals.

Listen now on Apple, Google, Spotify, TuneIn, and YouTube Audio

Jennifer Butler was appointed Executive Vice President and General Manager of Innate Pharma US Inc. in March 2019.

NIH Logo

Six months into the COVID-19 pandemic, the question of why tests that detect the presence of the SARS-CoV-2 virus are not faster, better, and cheaper in this country still remains. Despite an incredibly complicated answer, the National Institutes of Health (NIH) has announced that they are going to help some companies work to develop their technologies, with the hope of getting over this roadblock. The program will give $248.7 million to seven biomedical diagnostic companies. The money is intended to support a range of new lab-based and point-of-care tests that, they hope, could significantly increase the number, type, and availability of tests by millions per week as early as September 2020.


Rita Colwell

Rita Colwell is perhaps best known for her research on the pathogenic bacterium Vibrio cholerae. But the designation of pioneer is a label befitting Colwell for far-reaching contributions to many other areas, including her decades-long fight against sexism in a male-dominated field.

Colwell’s unique perspective on sexism in science is now able to be explored in her book, A Lab of One’s Own: One Woman’s Personal Journey Through Sexism in Science, which will be released on August 4th.


BioFactura Logo

FREDERICK, Md., July 29, 2020 /PRNewswire-PRWeb/ -- BioFactura, Inc. today announced a $1 million Small Business Innovation Research (SBIR) Phase II contract awarded by the Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the Department of Defense (DoD). The goal of this project is to develop, optimize, and scale-up a highly efficient mammalian cell culture-based bioprocess suitable to meet surge requirement needs for rapid manufacture of a monoclonal antibody (mAb) therapeutic against the Marburg virus (MARV) biothreat.


Johns Hopkins Medicine

BALTIMORE (WJZ) — Johns Hopkins Hospital ranked no. 3 among the nation’s best hospitals, according to U.S. News & World Report.

The Best Hospitals List was released Tuesday with The Mayo Clinic earning the no. 1 overall ranking this year, followed by Cleveland Clinic at no. 2 out of 4,500 hospitals.

U.S. News & World Report also ranked 12 specialties at Hopkins among the top 10 in the country. Ear, Nose, and Throat, Neurology and Neurosurgery, Psychiatry, and Rheumatology ranked no. 1.


TEDCO Announces New Executives Maryland curated tncontentexchange com

COLUMBIA, Md., July 28, 2020 /PRNewswire/ -- TEDCO, Maryland's economic engine for technology companies, announced today the appointments of Michael Hauser as the Managing Director of Investments and Terry Rauh as the Vice President, Chief Administrative Officer.

"Michael and Terry bring many years of leadership experience to fill these critical roles at TEDCO," said Troy LeMaile-Stovall, TEDCO's incoming CEO and executive director. "Leveraging their extensive knowledge of the Maryland business and innovation ecosystem, we're looking forward to the impact they will make in fostering TEDCO's mission."

Image: Michael Hauser, TEDCO

HemoShear Therapeutics Logo

Charlottesville, Va., July 28, 2020 – HemoShear Therapeutics, a clinical stage company developing treatments for rare metabolic disorders, has received Fast Track and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA) for HST5040, a once-daily oral small molecule drug being developed to treat methylmalonic acidemia (MMA) and propionic acidemia (PA).  

In June, HemoShear received clearance from the FDA for its Investigational New Drug application to conduct a phase 2 clinical study of HST5040 in patients with MMA and PA. MMA and PA are rare genetic disorders caused by the deficiency of certain enzymes required to metabolize amino acids.


Opinion Sputnik set off the Space Age This virus can spark the Health Age The Washington Post

Regina E. Dugan is chief executive of Wellcome Leap, a nonprofit that seeks breakthroughs in human health. From 2009 to 2012, she served as director of the Defense Advanced Research Projects Agency.

The global pandemic is a hinge in history. Hundreds of thousands of lives lost globally; trillions in economic damage. It is as if the 1918 flu and the 1929 crash happened in the same year. It is the kind of event that alters the course of history so much that we measure time by it: before the pandemic — and after. It is a Sputnik moment.

Image: Astronaut Buzz Aldrin walks on the surface of the moon on July 20, 1969. (Neil Armstrong/NASA via AP)

Hopkins spinoff Thrive Earlier Detection Corp raises 257 million funding round Baltimore Business Journal

Johns Hopkins cancer diagnostics spinoff Thrive Earlier Detection Corp. has raised $257 million in new funding a little over a year after it closed another huge round.

Thrive launched in May 2019 with $110 million in funding for its cancer-detecting blood test developed by researchers at Johns Hopkins. That Series A round was remarkable for its size. It was the largest ever raised in support of a Hopkins-licensed technology, and among the largest raised by any firm co-based in the Baltimore area.

Image: https://www-bizjournals-com


ROCKVILLE, Md., July 28, 2020 -- American Gene Technologies (AGT), an internationally recognized leading gene and cell therapy company in Rockville, Maryland, today announced it has leased a spacious, modern facility in the Maryland life sciences corridor, across from National Cancer Institute and Johns Hopkins Shady Grove Campus.



Future pandemics—and suffering of the kind inflicted by COVID-19—could be avoided if we troubled ourselves to see where dangerous pathogens lie in wait. We could, two unrelated studies suggest, save ourselves untold woe and conserve our fortunes if we were to look into matters geographic, zoologic, and genomic. More specifically, we need to keep our eyes wide open when we venture into the planet’s last wild places. There, we may run into wild animals that are infected with pathogens harboring wild genetic traits—which is to say, genetic traits that evolved naturally, beyond our gaze, and that waited patiently, perhaps decades, for a chance to strike.



Biotechnology led the healthcare industry in investment activity from private equity and venture capital during the first half of 2020, drawing nearly $12.60 billion in funding, up from $7.28 billion for the year-ago period.

The biotechnology sector either announced or concluded 342 deals globally as of June 30, comprising mergers and acquisitions and private placements, where the main investor was either a venture capitalist, a hedge fund manager or a private equity company, according to an analysis by S&P Global Market Intelligence.


johns hopkins logo

BALTIMORE (WJZ) — Johns Hopkins researchers have received over $30 million in funding from the U.S. Department of Defense for two nationwide clinical trials to test the effectiveness of a convalescent blood plasma outpatient treatment.

The treatment is a transfusion of a blood product from COVID-19 survivors that contains antibodies that may help the patient’s immune system fight the virus, researchers say.


Innate Pharma logo

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the publication of a Nature paper entitled, “Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis,” authored by Innate researchers in partnership with scientists from Hôpitaux Universitaires de Marseille AP-HM (La Timone and North Hospitals), Laveran Hospital, Aix Marseille University, the Centre d’Immunologie de Marseille-Luminy (Inserm, CNRS, AMU) and Marseille Immunopole/AP-HM immunoprofiling laboratory at La Timone Hospital.

This Marseille-based exploratory research taskforce, named EXPLORE COVID-19, analyzed immune cells in COVID-19 patients at different stages of the disease. The goal of the study was to gain translational insights to better understand the immune response in COVID-19 patients and identify potential targets to fight the viral infection.